Alhamarneh Osama, Amarnath Shoba M P, Stafford Nicholas D, Greenman John
Department of Otolaryngology, Head and Neck Surgery, Cancer Division, Postgraduate Medical Institute, Cancer Division, The University of Hull, Hull HU6 7RX, United Kingdom.
Head Neck. 2008 Feb;30(2):251-61. doi: 10.1002/hed.20739.
Advances in the treatment modalities for head and neck squamous cell carcinoma (HNSCC) over the last 20 years involving surgery, radiotherapy, chemotherapy, and immunotherapy are not fully reflected in increases in the 5-year survival rates, mainly due to locoregional recurrences and to a lesser extent, distant metastasis. This can, in part, be attributed to the fact that HNSCC induces severe depression of a patient's immune system. Recent advances in understanding the complex host-tumor interactions have led to the identification of a distinct suppressor cell population known as regulatory T cells that play a crucial role in maintaining T-cell tolerance to self-antigens. Here, we present a critical review of our understanding of the involvement of regulatory T cells in controlling the T-cell immune response in tumor occurrence and progression in HNSCC with an emphasis on current and future immunotherapeutic approaches involving regulatory T cells.
在过去20年里，头颈部鳞状细胞癌（HNSCC）的治疗方式取得了进展，包括手术、放疗、化疗和免疫疗法，但5年生存率的提高并未完全体现这些进展，这主要是由于局部区域复发，在较小程度上是由于远处转移。这部分可归因于HNSCC会导致患者免疫系统严重抑制。在理解复杂的宿主-肿瘤相互作用方面的最新进展，已导致识别出一种独特的抑制细胞群体，即调节性T细胞，它们在维持T细胞对自身抗原的耐受性方面发挥着关键作用。在此，我们对头颈部鳞状细胞癌肿瘤发生和进展过程中调节性T细胞参与控制T细胞免疫反应的理解进行批判性综述，重点关注涉及调节性T细胞的当前和未来免疫治疗方法。
